Comparison of the effect of pre-operative single oral dose of tramadol and famotidine on gastric secretions pH and volume in patients scheduled for laparoscopic cholecystectomy

Journal of the College of Physicians and Surgeons Pakistan

Volumn 25, Issue 5, 2015, Pages 320-323

  Khan, Mueen Ullah ^a   Aqil, Mansoor ^a   Hussain, Altaf ^a   Zahrani, Tariq Al ^a   Hillis, Marwan ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Famotidine; Gastric; PH; Tramadol; Volume

Indexed keywords

FAMOTIDINE; PLACEBO; TRAMADOL; ANTIULCER AGENT; NARCOTIC ANALGESIC AGENT;

ACID ASPIRATION; ADULT; ANESTHESIA INDUCTION; ARTICLE; CHOLECYSTECTOMY; CONTROLLED STUDY; ELECTIVE SURGERY; FEMALE; GENERAL ANESTHESIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PH MEASUREMENT; PREOPERATIVE EVALUATION; RANDOMIZED CONTROLLED TRIAL; SAUDI ARABIA; SINGLE DRUG DOSE; STOMACH JUICE; STOMACH PH; STOMACH SECRETION; STOMACH VOLUME; AGED; DRUG EFFECTS; GASTRIC MUCOSA; LAPAROSCOPIC CHOLECYSTECTOMY; ORAL DRUG ADMINISTRATION; PAIN, POSTOPERATIVE; PERIOPERATIVE PERIOD; PH; SECRETION (PROCESS); STOMACH ACID; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANALGESICS, OPIOID; ANESTHESIA, GENERAL; ANTI-ULCER AGENTS; CHOLECYSTECTOMY, LAPAROSCOPIC; ELECTIVE SURGICAL PROCEDURES; FAMOTIDINE; FEMALE; GASTRIC ACID; GASTRIC JUICE; GASTRIC MUCOSA; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; PAIN, POSTOPERATIVE; PERIOPERATIVE CARE; SAUDI ARABIA; TRAMADOL; TREATMENT OUTCOME;

EID: 84929673238     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Katz WA. Pharmacology and clinical experience with tramadol in osteoarthritis. Drugs 1996; 52:39-47.
2. Wilder-Smith CH, Bettiga A. The analgesic tramadol has minimal effect on gastrointestinal motor function. Br J Clin Pharmacol 1997; 43:71-5.
3. Reeves RR, Cox SK. Similar effects of tramadol and venlafaxine in major depressive disorder. South Med J 2008; 101:193-5.
4. Sagata K, Minami K, Yanagihara N. Tramadol inhibits norepinephrine transporter function at desipramine-binding sites in cultured bovine adrenal medullary cells. Anesth Analg 2002; 94:901-6.
5. Shiga Y, Minami K, Shiraishi M. The inhibitory effects of tramadol on muscarinic receptor-induced responses in Xenopus Oocytes expressing cloned M3 receptors. Anesth Analg 2002; 95:1269-73.
6. Shiraishi M, Minami K, Uezono Y, Yanagihara N, Shigematsu A. Inhibition by tramadol of muscarinic receptor-induced responses in cultured adrenal medullary cells and in Xenopus laevis oocytes expressing cloned M1 receptors. J Pharmacol Exp Ther 2001; 299:255-60.
7. Teabeaut JR. Aspiration of gastric contents; an experimental study. Am J Pathol 1952; 28:51-67.
8. Roberts RB, Shirley MA. Reducing the risk of acid aspiration during cesarean section. Anesth Analg 1974; 53:859-68.
9. Lintz W, Beier H, Gerloff J. Bioavailability of tramadol after i.m. injection in comparison to i.v. infusion. Int J Clin Pharmacol Ther 1999; 37:175-83.
10. Minami K, Ogata J, Horishita T, Shiraishi M, Okamoto T, Sata T, et al. Intramuscular tramadol increases gastric pH during anaesthesia. Can J Anesth 2004; 51:6:545-8.
11. Elhakim M, El-Megid A, Metry A, El-hennawy A, El-Queseny K. Analgesic and antacid properties of i.m. tramadol given before Caesarean section under general anaesthesia. Br J Anaesth 2005; 95:811-5.
12. Lintz W, Barth H, Osterloh G, Schmidt-Böthelt E. Bioavailability of enteral tramadol formulations. 1st communication: capsules. Arzneimittelforschung 1986; 36:1278-83.
13. Lintz W, Becker R, Gerloff J, Terlinden R. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 4th communication: drops (without ethanol). Arzneimittelforschung 2000; 50:99-108.
14. Osinaike BB, Ogunro PS, Oyebamiji EO, Ogungbamigbe TO. Effects of varying doses of tramadol on gastric pH. Anesth Essays Res 2013; 7:25-8.
15. Paranjothy S, Griffiths JD, Broughton HK, Gyte GM, Brown HC, Thomas J. Interventions at caesarean section for reducing the risk of aspiration pneumonitis. Cochrane Database Syst Rev 2014; 2:CD004943.
16. Abe K, Shibata M, Demizu A, Hazano S, Sumikawa K, Enomoto H, et al. Effect of oral and intramuscular famotidine on pH and volume of gastric contents. Anesth Analg 1989; 68: 541-4.
17. Echizen H, Ishizaki T. Clinical pharmacokinetics of famotidine. Clin Pharmacokinet 1991; 21:178-94.
18. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98:2616-20.
19. Edwards SJ, Lind T, Lundell L. Systematic review: Proton Pump Inhibitors (PPIs) for the healing of reflux oesophagitis- a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther 2006; 24:743-50.
20. Shrestha BR, Shrestha S, Moktan S, Shrestha OS. Gastric pH in patients premedicated with Esomeprazole or Famotidine undergoing routine surgery under general anaesthesia. J Kathmandu Med Coll 2012; 2:71-6.